A position of responsibility
Bringing and sustaining vital drugs to market safely, and as quickly as possible.
$1.3 million
awarded by the Foundation for Chemistry Research and Initiatives (FCRI) toward a multidisciplinary program with MatTek Corporation to develop a New Approach Methodology (NAM) inhalation toxicology test
100
IND submissions containing Retrogenix® platform data supported across multiple regulatory bodies (FDA, EMA, and PMDA)
News and Insights
Featured Story
Advancing Therapeutic Delivery in CNS Diseases
Featured Story
Finding the Cure for Childhood Cancer and Rare Diseases
Events and Training
Dec 15 - 18, 2024 | San Diego, CA | Conference
Antibody Engineering & Therapeutics
Jan 20 - 23, 2025 | Dallas, TX | Booth #235 | Conference
Advanced Therapies Week 2025
Mar 25 - 27, 2025 | Charleston, SC | Symposium
QC Micro Summit 2025
Supporting the full drug discovery and development continuum
No matter where you are in your drug development journey, we can provide you with a wide range of products, models, services and guidance that are tailored to your specific needs.
Support your basic research with help from the leading global supplier of laboratory animal models and services.
The leading developers of cutting-edge cell therapies and basic research trust us as their cell sourcing provider.
Genetically Engineered Animal Models and Services (GEMS) team helps you select, customize, and maintain the right mice for your research. Services for genetically engineered animals include mouse and rat model creation, breeding, genotyping, and mouse embryo and sperm cryopreservation.
Reduce time to clinic by up to a year with an integrated drug discovery approach in which target discovery, hit id, hit-to-lead, lead optimization, safety, and toxicology are all managed by the same project team.
In vitro to in vivo translation is difficult, costly, and often fails. Advance your discovery research with our translationally focused approach across a range of therapeutic areas including oncology, neuroscience, and immunology.
Antibody discovery services designed with your IND in mind. Comprehensive solutions, tailored to your unique vision for your next antibody therapeutic.
Two primary study offerings are available for non-GLP toxicology studies for lead optimization and preclinical development.
Successfully initiate and complete your IND-enabling program while meeting regulatory expectations with our unique range of IND-enabling studies.
Our carcinogenicity studies include expert support in project design, model selection, and in vivo and ex vivo data for final submission.
Our tailored global testing and manufacturing services support clients throughout the biologic development cycle, from discovery through preclinical and clinical studies to marketed product release.
Accelerate the development of your biopharmaceutical from concept to cure with our CGMP compliant biologics contract manufacturing services.
A flexible testing platform that can be deployed where and when you need it, whether it’s located at your facility, one of our satellite labs, or even within the walls of the many Charles River facilities itself.
Fastrack your cell and gene development and manufacturing with our end-to-end scalable solutions from early stage-research and testing through commercial release.
Navigate seamlessly throughout the biologic development cycle, from early concept to market-ready with our tailored, CGMP global testing and manufacturing solutions.
Elevate your contamination control strategy and accelerate production with confidence. Our rapid, accurate, and compliant microbial testing solutions optimize your QC workflow.
One Step by Charles River is a comprehensive, tailored suite of CRO drug discovery and development services in target discovery, lead optimization, development chemistry, GMP, drug product development and CMC strategy.
Expedite your investigational new drug (IND) application with Fast Lane Paradigm. Learn how to reduce white space between studies and accelerate time to clinic for you INDs.
Charles River can conduct an investigational new drug (IND) study from start to finish, and offers stand-alone studies needed for IND-enabling submissions. Our IND experts have expertise in all major therapeutic areas, including medical devices and gene and cell therapies.